<DOC>
	<DOCNO>NCT02263495</DOCNO>
	<brief_summary>Metastatic breast cancer ( MBC ) incurable disease need improve effective chemotherapy . Paclitaxel plus Gemcitabine ( PG ) combination chemotherapy one prefer chemotherapeutic regimen patient MBC , find proper maintenance chemotherapy regimen survival benefit feasible toxicity profile show large phase III KCSG ( Korean Cancer Study Group ) study ( Park Y et al . J Clin Oncol 31 ( 14 ) :1732 , 2013 ) . Eribulin mesylate microtubule-targeting agent show improved overall survival benefit monotherapy MBC patient new chemotherapeutic agent failure anthracycline taxane EMBRACE study ( Cortes J et . al . Lancet 377:914-923 , 2011 ) . Eribulin also report promising efficacy another randomized phase III study demonstrate eribulin efficacious capecitabine ( Kaufman P et . al . Abstr # S6-6 , SABCS 2012 ) . Both study result show potential clinical benefit patient triple negative MBC ( TNBC ) . Thus , eribulin combine gemcitabine may new potential regimen early line therapy patient metastatic breast cancer . Furthermore , eribulin may rational benefit compare paclitaxel term neurotoxicity . Although direct evidence eribulin well neurotoxicity profile taxane , eribulin tend show less neurotoxicity compare ixabepilone phase II trial ( Vahdat , L et al . 2011 SABCS ) . Eribulin worsen toxicity compare paclitaxel . Therefore , EG may less neurotoxicity compare PG . In phase I trial , eribulin combination gemcitabine feasible patient advance solid tumor treat chemotherapy ( &lt; 3 line ) ( Goel R , et al , 2009 ASCO ) . Based rationale , investigator conduct randomize phase II study compare EG chemotherapy PG chemotherapy patient HER-2 negative MBC first-line chemotherapy . A total 112 patient recruit . Patients randomize treatment arm permutated method . The randomization ratio 1:1 . This study multi-center , randomize , open label study .</brief_summary>
	<brief_title>Eribulin Plus Gemcitabine ( EG ) v Paclitaxel Plus Gemcitabine ( PG ) HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>A total enrol 112 patient EG PG group , provide chemotherapy regimen : Paclitaxel/Gemcitabine ( PG ) : every 3 week D1 Paclitaxel 175mg/m2 + D5W 500mL MIV 3hrs gemcitabine administration D1 , D8 Gemcitabine 1,250 mg/m2 + NormalSaline 100ml MIV 30mins - Pre &amp; Post medication ( change accord institution ' policy ) D1 Corticosteroid 100 mg i.v . 30 min . Paclitaxel Pheniramine 1A + D5W 50mL MIV 30mins Paclitaxel Ranitidine 50mg IV + D5W 50mL MIV 30mins Paclitaxel HT3 antagonist 1A + D5W 50 mL MIV 30mins Paclitaxel Eribulin/Gemcitabine ( EG ) : every 3weeks D1 , D8 Eribulin 1.0 mg/m2 , 2-5min iv gemcitabine ( miv NormalSaline 100ml max . ) D1 , D8 Gemcitabine 1000 mg/m2 + NormalSaline100ml MIV 30mins &lt; schedule Assessment adn procedure ( ±3 day window period ) &gt; 1. screen /baseline - obtain Informed consent form - collect information - demographic data - breast cancer treatment history/ medical history - general physical examination/ vital sign &amp; Performance status - Test : CBC/blood chemistry/ Tumor response ( CT MRI ) / - collect QOL questionnaire use FACT-Taxane 2. cycle 1 ~ prior EOT - general physical examination/ vital sign &amp; Performance status - Test : CBC/blood chemistry/ Tumor response ( CT MRI ) - collect QOL questionnaire use FACT-Taxane - administration PG EG 3 . EOT ( end treatment ) - general physical examination/ vital sign &amp; Performance status - Test : CBC/blood chemistry/ Tumor response ( CT MRI ) - collect QOL questionnaire use FACT-Taxane 4. survival follow ( every 12weeks ) - survival - anti neoplastic therapy end treatment - The tumor response perform every 12 ( ±2 ) week disease progression &lt; WITHDRAWAL OF SUBJECTS &gt; Subjects may withdraw study ( i.e . study medication study procedure ) follow reason : - At request - If , investigator 's opinion , continuation study would detrimental subject 's well-being - In case disease progression - In case unacceptable toxicity</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm metastatic , recurrent breast cancer 2 . HER2negative breast cancer 3. age &gt; 18 year 4 . ECOG performance status 0 2 5 . Pre postmenopausal breast cancer patient measurable nonmeasurable lesion , candidate chemotherapy 6 . Life expectancy ≥ 3 month 7 . No prior history chemotherapy metastatic , recurrent breast cancer 8 . Patients may receive prior neoadjuvant adjuvant taxane regimen long 12 month since completion regimen . 9 . Patients either may may prior anthracycline contain regimen . 10 . Prior hormonal therapy treatment metastatic disease allow . But antitumoral hormonal therapy must terminate prior enrollment ( date randomization ) 11 . Prior radiation therapy allow long &lt; 25 % bone marrow treat , patient must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Prior radiotherapy must complete 2 week study entry . 12 . Bisphosphonates treatment bone metastasis initiate follow first dose randomized therapy . It must initiate prior day treatment ( cycle 1 , day 1 ) . Patients may continue bisphosphonates already establish bisphosphonate therapy bone metastases 13 . Adequate bone marrow function ( ≥ ANC 1,500/ul , ≥ platelet 100,000/ul , ≥ Hemoglobin 9.0 g/dl ) 14 . Adequate renal function ( ≤ serum creatinine 1.5 mg/dl CCr ≥ 50 ml/min ) 15 . Adequate liver function ( ≤ serum bilirubin 1.5 mg/dl , ≤ AST &amp; ALTX3 upper normal limit AST ALT ≤ 5.0XULN judged investigator relate liver metastasis ) 16 . Written inform consent 1 . Serious uncontrolled intercurrent infection 2 . Serious intercurrent medical psychiatric illness , include active cardiac disease 3 . Pregnancy breast feed 4 . Second primary malignancy ( except situ carcinoma cervix adequately treat nonmelanomatous carcinoma skin malignancy treat least 5 year previously evidence recurrence ) 5 . Documented parenchymal leptomeningeal brain metastasis 6 . Peripheral neuropathy ≥ grade 2 7 . Prior treatment gemcitabine allow . 8 . HER2 overexpressing breast cancer concomitant trastuzumab treatment allow 9 . Women childbearing potential , unwilling use medically acceptable method contraception trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HER2-Negative</keyword>
</DOC>